Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Graft vs Host Disease 2Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 3ruxolitinib 2axatilimab 1Sirolimus 1Rituximab 1Proto-Oncogene Proteins c-raf 1Prednisone 1Photopheresis 1Pentostatin 1Mycophenolic Acid 1Methylprednisolone 1Methotrexate 1Infliximab 1Imatinib Mesylate 1Everolimus 1Abatacept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Graft vs Host Disease × ruxolitinib × Clear all
NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT02953678 2021-11-24

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Incyte Corporation

Phase 2 Completed
71 enrolled 24 charts 1 FDA

Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡